Cubist Systematic Strategies, LLC Pro Qr Therapeutics N.V. Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.99 - $3.66 $31,354 - $57,666	15,756 Added 18.48%	101,003 $215,000
Q4 2022 Feb 14, 2023	BUY	$0.8 - $3.7 $68,197 - $315,413	85,247 New	85,247 $315,000
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.0 $8,064 - $14,400	-14,400 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.9 - $8.39 $12,327 - $114,917	13,697 Added 1948.36%	14,400 $13,000
Q4 2021 Feb 14, 2022	SELL	$6.58 - $8.44 $158,301 - $203,049	-24,058 Reduced 97.16%	703 $6,000
Q3 2021 Nov 15, 2021	SELL	$5.16 - $8.47 $66,682 - $109,457	-12,923 Reduced 34.29%	24,761 $207,000
Q2 2021 Aug 16, 2021	BUY	$5.75 - $7.59 $128,449 - $169,553	22,339 Added 145.58%	37,684 $254,000
Q1 2021 May 17, 2021	BUY	$4.14 - $9.22 $63,528 - $141,480	15,345 New	15,345 $101,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.